Compare Cintas Corporation (CTAS) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cintas Corporation vs Regeneron Pharmaceuticals Inc — how do they compare? Cintas Corporation trades at $205.78 (market cap $81.25B), while Regeneron Pharmaceuticals Inc trades at $796.32 (market cap $83.19B). The key difference: Cintas Corporation and Regeneron Pharmaceuticals Inc are close in size by market cap, and Cintas Corporation pays the higher dividend (1.02%). Which is the better fit depends on your goals.
| CTAS | REGN | |
|---|---|---|
Market Cap | $81.25B | $83.19B |
Sector | Industrials | Health |
52-Week High | $225.10 | $812.27 |
52-Week Low | $163.55 | $545.94 |
Enterprise Value | $83.67B | $77.90B |
Dividend Yield | 1.02% | 0.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cintas (CTAS) trades at $203.05, up 0.45% on the day, with a bullish technical signal and strong fundamental performance. The company reported Q2 2026 EPS of $1.29, beating estimates, and revenue growth continues with a 17.75% net income margin. Recent news highlights Bank of America's upgrade to 'Buy' and a quarterly dividend announcement, reflecting confidence in its outlook.
The outlook for CTAS is positive, supported by consistent earnings beats and robust profitability, though high valuation multiples like a P/E of 41.35 pose a risk. Upside exists toward the consensus price target of $225.83, but investors should monitor competitive pressures and economic sensitivity.
Regeneron Pharmaceuticals (REGN) trades at $784.36, up 1.59% today, with a bullish technical signal from moving averages but overbought RSI readings. The company shows strong profitability with a net income margin of 27.86% and has beaten EPS estimates in recent quarters. However, multiple class-action lawsuits filed in August 2026 allege inadequate clinical-trial risk disclosures, creating investor uncertainty amid solid financial performance.
Outlook remains supported by earnings momentum and analyst buy ratings, but legal risks and high valuation multiples pose near-term headwinds. Investment opportunity hinges on legal resolution and sustained drug pipeline success, while risks include trial setbacks and regulatory scrutiny.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cintas Corporation
In its core uniform and facility services unit (78% of sales), Cintas provides uniform rental programs to businesses across the size spectrum, mostly in North America. The firm is by far the largest provider in the industry. Facilities products generally include the rental and sale of entrance mat, mops, shop towels, hand sanitizers, and restroom supplies. Cintas also runs a first aid and safety services business (11% of sales), a fire protection services business (7% of sales), and a uniform direct sales business (4% of sales).
Read more on CTAS →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
